Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Abstract

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to previous disease-modifying anti… (More)
DOI: 10.2165/11595920-000000000-00000

Topics

4 Figures and Tables